

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method of treating pathogenic polyclonal B cell activation or class switching in a patient, the method comprising:

administering to said patient an effective dose of a CD1 blocking antibody or fragment thereof, wherein said antibody or fragment thereof binds to CD1, and interferes with T cell recognition of CD1;

wherein said dose is effective to reduce the pathogenic symptoms of said polyclonal B cell activation or class switching and wherein said pathologic polyclonal B cell activation or class switching results in systemic lupus erythematosus in said patient.

2-5. (canceled)

6. (previously presented) The method according to Claim 1, wherein said antibody is a monoclonal antibody.

7. (original) The method according to Claim 6, wherein said monoclonal antibody is a human or humanized antibody.

8. (previously presented) The method according to Claim 6, wherein said monoclonal antibody specifically binds to human CD1d.

9. (canceled)

10. (previously presented) The method according to Claim 6, wherein said antibody comprises a cocktail of monoclonal antibodies that bind to multiple human CD1 isotypes.

11. (canceled)

12. (currently amended) The method according to Claim 1 Claim 2, wherein said administration is by intravenous injection.

13. (currently amended) A method according to Claim 1 Claim 2, further comprising administering to said patient a second therapeutic agent which is an immunosuppressant, anti-inflammatory, or anti-coagulant agent for the treatment of systemic lupus erythematosus.

14. (canceled)

15. (new) A method of treating systemic lupus erythematosus in a patient comprising administering to said patient an effective dose of a CD1d antibody, wherein said effective dose treats said systemic lupus erythematosus in said patient.

16. (new). The method of Claim 15 wherein said administration inhibits a pathologic polyclonal B cell activation or class switching.

17. (new) The method according to Claim 15, wherein said antibody is a monoclonal antibody.

18. (new) The method according to Claim 17, wherein said monoclonal antibody is a human or humanized antibody.

19. (new) The method according to Claim 17, wherein said monoclonal antibody specifically binds to human CD1d.

20. (new) The method according to Claim 15, wherein said administration is by intravenous injection.

21. (new) A method according to Claim 15, further comprising administering to said patient a second therapeutic agent for the treatment of systemic lupus erythematosus.

22. (new) The method of Claim 21 wherein said second therapeutic agent is a non-steroidal anti-inflammatory drug, corticosteroid, immunomodulating drug, and/or an anticoagulant.